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(Opinion expressed 24 June 1977) 
TERMS OF REFERENCE 
To give am opinion on the toxicological acceptability of the use of saccharin in food· 
CONCLUSIONS 
1. The temporary ADI of 0-2.5 mg/kg bw proposed by JEFCA is endorsed . 
2· There is a need for a specification, listing detailed purity criteria, which includes 
appropriate limits for impurities« 
3· Saccharin should not be used in food specially prepared for young children (up to 3 years 
old). 
4· The intake of saccharin by children and pregnant women should be limited. To facilitate 
this limitation the Committee is of the opinion that the consumer should be adequately 
informed of the presence of saccharin in any food. 
INTRODUCTION 
Saccharin was first synthesised by Constantine Fahlberg in 1879· Its potential as a 
sweetening agent was quickly recognised and it was soon used as a substitute for sugar in 
sweets and bakery products. It is well known that the material may be manufactured by the 
Remsen - Fahlberg technique or the Maumee process. The latter is used predominantly in the 
USA and Canada. Furthermore, the compound-may be in the form of a free acid, the sodium or 
calcium salt. A summary of the two processes is given in Annex I. 
Feeding studies conducted at the Wisconsin Alumni Research Foundation (WARF) and the Food 
and Drug Administration (FDA) indicated some time ago that saccharin at high dosage 
produced tumours in the bladders of male rats (l,2). However, these findings were not 
supported by similar studies in rats, mice, hamsters and monkeys in 7 other laboratories 
(2 to 5). 
Quite recently the Health Protection Branch in Canada have carried out a two—generation 
study in Sprague Dawley rats and it has been found that there is an increased incidence 
of bladder cancer in the male rat. 
In assessing the problem of saccharin, the Committee believed that in the Report it would be 
useful to outline some of the previous history of the subject, and to assess all available 
animal and human data of which it was aware. For this purpose the Report is divided into 
the following headings: 
A. Chemical : 1. Specifications and Impurities 
B. Biological: 2. Metabolism 
3. Mutagenicity/Teratogenicity 
4. Chronic Studies 
C. Human : 5· Epidemiology 
Some members of the Committee felt that saccharin should not be used in food for general 
consumption. A. CHEMICAL CONSIDERATIONS 
1. Specifications and Impurities 
Because of the findings with respect to the WARF and FDA study, the Canadians decided, 
as did the Battello Institute, that they would analyse various samples of saccharin for 
the impurity ortho-toluene-sulphonamide (OTS). They found that in the Remsen-Fahlberg 
technique, levels of this impurity were present in the range 6,100 to 118 ppm. With 
respect to the Maumee process, the levels vary between 25 and less than 1 ppm. 
The impurities present in saccharin have been studied by several workers (6,7) some of 
which have been identified in amounts as low as 0.1 mg/kg. Several of these impurities 
are listed below. 
diphenylsulphone 
tetracosane 
o—sulphamylbenzoic acid 
ρ—sulphamylbenzoic acid 
o—t oluenesulphonamide 
ρ—toluenesulphonamide 
1,2—benezisothiazole l,l-<Lioxide 
1,2—benzisothiazoline 1,1-dioxide 
ρ, p-d i t ol yl sul ph one 
o, ó-dit ol yl sul ph one 
o,m-dit ol yl sul ph one 
o, p-dit olyl sul ph one 
m,p-ditolylsulphone 
Unpublished information (Dr. Lafontaine) has shown yet other impurities might be present 
(e.g. p-toluenesulphonamide as a major impurity of saccharin produced by the Remsen-
Fahlberg process; and in saccharin produced by the Maumee process, p—nitrobenzoic acid 
and certain phthalates - for instance dibutylphthalate have been tentatively identified). 
The saccharin used in food should be as pure as is practicable by good tecbnicological 
practice. The Committee recommends that saccharin for food use should comply with a 
detailed specification giving limits for the different impurities. These limits should 
take into consideration the chemical nature and toxicological properties of the 
impurities. 
B. BIOLOGICAL CONSIDERATIONS 
2. Metabolism 
Several studies have been carried out on the metabolism of saccharin in man and these 
early studies showed that it was relatively rapidly excreted, mainly in the urine in the 
unchanged state (8 and 9)· These studies as far back as 1905 have recently been repeated 
by other workers using the monkey, rat and several other species and no worker has been 
able to detect any bio-transformation products (10 and 12). 
Recent work (13) has shown that when C\¿ labelled saccharin was administered orally to 
rats on a normal diet fed both 1$ and 5$ saccharin for up to 12 months, some 90$ of the 
dose was excreted within 24 hours, the major amount in the urine (up to 80$) and the 
remaining 20$ in the faeces. It has been stressed that no metabolite was detected in 
the excreta by chromatography or reverse isotope dilution techniques. The same work 
(l3) showed that no metabolite was detected in man after the ingestion of 1 gm of 
saccharin daily for 21 days. 3. Metagenicity and Teratogenicity 
It has recently been shown that a particular batch of sodium saccharin does not induce 
mutations by the Ames assay technique and that 5—chlore—saccharin is also negative. 
Ashby has shown that all saccharins by examinations of both the Ames and cell transform-
ation tests have given negative results (14)· 
Professor Lederer using saccharin prepared from the two processes — Remsen-Fahlberg, and 
Maumee studied the resorption of the foetus of pregnant rats with various levels of the 
saccharins and with each of the following impurities: 
o—toluene sulphamide (OTS) 
p—toluene sulphonamide 
o—sulphamoylbenzoic acid 
p-sulphamoylbenzoic acid 
o—sulphobenzoic acid 
p-sulphobenzoic acid 
and ammonium o—sulphobenzoic acid 
He examined changes in the retina crystalline lens and optic nerve using a teratogenic 
index based on the gravity of the lesion. The changes seemed to be related solely to 
the impurities shown to be present in commercial saccharin. (Tables 1 and 2)(l5)(l6)(l7) 
(18)(19). 
4. Chronic Studies 
After considering the WARF and FDA studies, it was decided in Canada that because these 
findings were not supported by similar studies using rats, mice and hamsters at other 
laboratories, it would be useful to carry out a two—generation study involving the 
exposure of the F-, generation in utero. They felt that the discrepancies between the 
results of various studies also suggested that impurities (in particular OTS) in commer-
cial saccharin might be involved in the development of bladder cancer. They therefore 
decided that they would set up an OTS and 5$ sodium saccharin study to elucidate the 
problem. 
A full clinical assessment of these animals has been carried out throughout the time of 
the study and furthermore all animals have been autopsied and the individual reports 
on these are available. 
The main issue that has emanated from the interim report of the Canadian study is the 
fact that there is an increased incidence of bladder carcinoma in the male animals of 
the Fn and F.. generations. (Table 3) 
The Canadian workers have stressed that there has been a low incidence of kidney stones 
and they have found no evidence of the bladder parasite Tricosomoides Crassicouda or its 
ova. The Committee was aware that in Canada examination of the bladder sections revealed 
little evidence of pre-malignant lesions such as hyperplasia and metaplasia. The tumours 
found had arisen de novo and the criterion for judging malignancy was one of invasion of 
either the stalk of the papillary lesion seen, the sub mucosa or the muscle wall. The 
typical transitional cell carcinoma was a rarity as most of the lesions were anaplastic 
with accompanying invasion. 
With respect to saccharin causing malignancy in the male rat urinary bladder, some work 
has shown that the compound does accumulate in the bladder wall of the male. The defect 
of this work is that it has not been carried out in both males and females and at the 
present moment is being investigated in the United Kingdom (14)· 
Other studies which have been carried out are shown in Table 4 and the majority of these 
studies in all other species are negative. 
On the basis of the animal studies, the Committee endorsed the temporary ADI of 0—2.5 
mg/kg/bw/day established by JECFA (April 1977) for total intake of saccharin. However, 
this will have to be reassessed in the light of new information as it becomes available. 
The Committee also recognises that the regulatory application of an ADI is complicated by the sale and use of the substance in tablet form, and by the various types of legislation 
used to control its use (e.g. as food additive or as drug). The Committee did not 
believe that its terms of reference would permit it to enter into detailed discussion of 
this aspect but noted that it would appear that an ADI of this magnitude might require 
a limitation of the foodstuffs in which saccharin is used. Indeed, some Members of the 
Committee felt that saccharin should not be used in food for general consumptions (46)· 
C. HUMAN CONSIDERATIONS 
5. Epidemiology 
Studies so far published have been carried out to ascertain the relationship between 
artificial sweetener consumption and bladder cancer risk reveal no correlation. (37)-(45) 
However, these studies are not entirely satisfactory from the point of view of sample 
population and size. At the same time they are not solely related to sweeteners but 
deal also with other factors such as smoking. More recent epidemiological studies have 
produced conflicting results . In view of this the Committee recommends that prospective 
epidemiological studies should be carried out on the incidence of certain chronic state 
diseases in populations with a high intake of saccharin. 
After considering all the negative data presented (i.e. data showing no effects), the 
positive data in the WARF and FDA animal studies and the latest interim results of the 
latest animal study in Canada, the Committee believes that it is particularly important 
that the intake of saccharin by children and pregnant women be limited. To facilitate 
this limitation the Committee is of the opinion that the consumer should be adequately 
informed of the presence of saccharin in any food. The Committee recommends that 
saccharin should not be used in food specially prepared for young children (up to 3 
years old). 
The Committee was quite aware that a risk/benefit assessment might be made for critical 
population groups (such as diabetics, and those suffering from diseases originating 
from obesity). The Committee thought that these individuals should be guided by their 
physician. The Committee agreed that the situation should be kept under review as 
further data become available. 
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12 LIST OF TABLES Table 1 Development of gestation in the rat receiving saccharin or 
its impurities in the food ration 
contro] s 
saccharin 
Re-sen 3$ 
saccharin 
Remsen 0.3$ 
saccharin 
Maumee 3$ 
saccharin 
Maumee 0.3/i 
sacchaTi.il 
Maumee 0.15$ 
o—toluenesulphc— 
Hamide 0.1$ 
o—sul phamoylb en-
zoic acid, 0.1$ 
c—sulphobenzoic 
acid, 0.1$ 
ammonium—o—sulpho­
benzoic acid 0.1$ 
ne. 
moth­
ers 
52 
35 
13 
20 
28 
22 
20 
24 
20 
20 
no.  af embryos 
total 
9th 
rta.y 
465 
284 
123 
192 
271 
202 
I84 
221 
I87 
186 
20th 
day 
417 
188 
79 
164 
257 
182 
165 
187 
158 
141 
per r 
9th 
day 
9.1 
8.1 
9.6 
9.6 
9»7 
9.2 
9.2 
9.2 
9.3 
9.3 
ηother 
20th 
8.1 
5.4 
6.1 
8.2 
8.9 
8.2 
8.25 
7.8 
7.9 
7.0 
Resorotions 
10.3 
33.4 
36.4 
14.6 
8.3 
10.9 
10.3 
20.0 
15.I 
24.1 
Mass 
ar.br. 
(3) 
3 095 
3 204 
3 284 
3 209 
3 161 
3 142 
2 969 
3 208 
3 172 
2 983 
in mg 
Flacen, 
(ρ) 
470 
548 
452 
5C5 
440 
462 
522 
482 
470 
517 
Ratio 
Ε/Ρ 
6.6 
5.8 
7.3 
6.3 
7.2 
6.3 
5.1 
6.6 
6.7 
5.7 
Tabie 2 Teratogenic Index for two kinds of saccharin and their impurities 
administered by mouth 
Treatment 
controls 
saccharin Remsen 3$ 
saccharin Remsen 0.3$ 
saccharin Maumee 3$ 
saccharin Maumee 0.3$ 
saccharin Maumee 0.15$ 
0—toluenesulfonamide 0.1$ 
0—sulphamoylbenzoic acid 0.1$ 
0—sulphobenzoic acid 0.1$ 
ammonium—0—sulphobenzoic acid 0.1$ 
Teratogenic 
Index 
0.75 
6.38 
5.36 
0.00 
2.33 
0.00 
2.42 
6.42 
10.16 
5.68 
15 Table 3 Incidence of urinary tract tumour 
MALES: 
TREATMENT 
CONTROL 
2.5 MG/KG/DAY OTS 
25 MG/KG/DAY OTS 
250 MG^CG/DAY OTS 
25O MG/KG/DAY OTS 1$ NH.CI 
5$ Na SACCHARIN 
Fo GENERATION (l) 
BENIGN 
1 
1 
0 
1 
0 
5(3) 
MALIGNANT 
0 
0 
0 
0 
0 
3 
F GENERATION (2) 
BENIGN 
0 
0 
0 
0 
0 
4 
MALIGNANT 
0 
0 
0 
0 
0 
9(4) 
FEMALES: 
CONTROL 
2.5 MG/KG/DAY OTS 
25 MG/KG/DAY OTS 
250 MG/KG/DAY OTS 
25O MG/KG/DAY OTS 1$ NH CI 
5$ Na SACCHARIN 
0 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
o(5) 
0 
2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
2 
(1) 87 weeks on test before first tumour was observed. 
Male — Control — 36 5$ Na saccharin — 38 
Female — Control — 38 5$ Na saccharin — 40 
(2) 67 weeks on test before first tumour was observed. 
Male — Control — 42 5$ Na saccharin - 45 
Female - Control - 47 5$ Na saccharin - 49 
(3) Four (4) bladder tumours plus one (l) urethral tumour. In addition, there was one 
malignant lesion of the kidney pelvis not indicated. 
(4) Eight (8) bladder tumours plus one (l) urethral tumour. 
(5) There were two (2) malignant lesions of the kidney pelvis not indicated. 
16 Table 4 Saccharin animal laboratory studies 
Reference  Type  and 
of study 
Duration  Comments  Results 
20 
21 
22 
23 
24 
25 & 26 
27 & 28 
29 
30 
31 
32 
33 
34 
35 
36 
Rats 
Acute: Rats, mice, rabbits 
: Gestating Q mice 
Subacute: 4 groups rats 
: 1 group of rats 
: 3 groups of dogs 
Chronic: 2 groups of rats 
: dogs 
2 groups of 50 Q mice 
4 groups of 80 rats 
4 groups Q Swiss mice 
Tumours in 20+ in each of 2+ 
trials in same/de.ff. labs. 
4 groups of 50 Wistar rats 
Sprague—Dawley rats 
Inhibitory effects on AAF fed 
Q rats 
Groups of rhesus monkeys 
Review of mutation research 
Syrian Golden hamsters 
Groups of 60 0/6O Q Chas River 
rats 
I86 rats and mice 
Six generation study with mice 
including long term studies with 
P. F3 and F4 
2 yrs 
5 days 
38 days 
16 days 
30 days 
6 mths 
11 mths 
18 mths 
To 105 wks 
To 400 days 
To 56 wks 
Lifetime 
40 wks 
5.4 yrs+ 
8 days life 
26 mths 
2 yrs 
2 yrs 
1 & 5$ 
10:1 cyc/sacc 
0:1 & .5$ 
10:1 & .5$ 
1 g/kg & 10:1 
0,2,4, gAg 
2$ & 10:1 
0.065 gAg 
5$ (pre-treat 
PEG or PEG & BP 
W/ 
IP) 
0,500,1120,2500 
mgAg daily 
20$ sacc pellets 
2.0 gAg""
 w/
o
r 
w/out MNU 
100,250 mgAg or 
10:1 cyc/sacc 
5$ 
0,20,100,500 mg/ 
kg daily 
0,0.625,1.25,2.5, 
5,10$ 
0,90,270,810, 
2430 mgAg 
5$ & 1$ 
0.1 & 0.5$ sacc 
Slight effect 
at 5$ 
Negative 
Negative 
Negative 
Negative 
Negat ive 
Negat ive 
Negative 
Negat ive 
+ in 25OO 
mg grp 
+ for co—car. 
effect 
Negative 
Negative 
Negative 
+ or — 
Negative 
Negative 
Negative 
Negative for 
carcinogenicity 
embryogenicity 
and terato-
genicity 
ï: ANNEX I 
PRODUCTION OF COMMERCIAL SACCHARIN 
Summary of Remsen and Fahlherg, and Maumes methods CH. 
"^ 
+ HOSO Cl 
CH. 
so2ci 
+ para-isomer 
(Λ)  (B) 
(B) + NH. 
CH. 
S02NH2 
(C) 
(c) Oxidation, 
COOH  r^^ 
SO Jul„
 H2
S04 
C - O 
NH 
S' 
M 
O O 
(D)  (E) 
w 
*j 
i (F) 
G 
0 
\ 
/ 
0 + NH. 
(G) 
0 
II 
c 
c 
II 
0 
\ 
/ 
NH Hoffman degradation 
COOH 
HU-
GO 
(H) + Na2N02 + H2S04 
COOH 
N
+ = N 
(J) 
HSO 
COONa 
S~ 
(K) 
(K) + H
+ + CH3OH ψ 
O 
I! 
C - OCH. 
(L) 
(L) + Cl, 
O 
II 
C - OCH. 
so2ci 
NH. 
C = Ο 
^^ 
Ml 
S^ 
η 
0 0 
¡ 
(M)  (E) ANNEX I 
KEY TO ABBREVIATIONS USED 
(A 
(B 
(C 
(D 
(E 
(F 
(G 
(H 
(J 
(K 
(L 
(M 
t oluene 
o—t oluenesulphonylchioride 
o—t oluene sulph onamide 
o—sulphamoylbenzoic acid 
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disulphide ester of H 
o—carbethoxybenzene sulphonyl chi ori de 
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23 REPORT OF THE SCIENTIFIC COMMITTEE FOR FOOD ON CALCIUM DISODIUM 
ETHYLENEDIAMINE TETRA-ACETATE 
(Opinion expressed 24 June 1977) 
TERMS OF REFERENCE 
To give an opinion on whether calcium disodium ethylenediamine tetra—acetate (calcium 
disodium EDTA) could, from the point of view of safety-in—use, be added to the Community 
list of antioxidants for use in food. 
CONCLUSIONS 
1. The Committee endorsed the ADI established by JECFA for calcium disodium EDTA of 0-2.5 
mgAg body weight. 
2. Calcium disodium EDTA is acceptable as an additive for use in food within this limit and 
can, from the point of view of safety—in—use, be added to the Community list of anti-
oxidants for use in food. 
3. Calcium disodium EDTA should not be used in food intended for consumption by infants less 
than 2 years of age. 
BACKGROUND 
1. The present Directive on the approximation of the laws of the Member States concerning 
the antioxidants authorised for use in foodstuffs intended for human consumption 
(70/357/EEC of I3/7/1970K1) does not provide for the use at Community level of calcium 
disodium EDTA. 
2. The Treaty of Accession (2) and a modification to the Directive (74/412/EEC) of 1/8/1974) 
(3) permit Member States, until 31 December 1977, to maintain the provisions of their 
national laws authorising the use of this substance. 
3. The Commission is considering whether or not it should propose to the Council that 
calcium disodium EDTA should be included in the Directive and has asked the Scientific 
Committee for Food for its opinion. 
DISCUSSION 
1. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) considered a number of data 
at its 9th (4) and 17th (5) meetings. JECFA considered that the level causing no 
toxicological effect in the rat was 0.5$ in the diet equivalent to 250 mgAg bw. JECFA 
estimated that the acceptable dialy intake for man was 0—2.5
 mgAg bw. 
2. The Committee examined all of this information and also took into account subsequent 
short—term studies. It endorsed the ADI established by JECFA of 0—2.5 nig/kg bw. 
3. However, the Committee points out that in certain circumstances calcium disodium EDTA 
is used in human therapy for the treatment of heavy metal intoxication. The Committee 
was informed that calcium disodium EDTA had only been requested for use in certain 
well—specified products of low consumption. In these circumstances, the Committee 
felt that the use of this product could be accepted, but stressed that attention 
should be paid to ensure that the ADI was not exceeded if new uses were to be envisaged. 
The Committee would wish to re—evaluate calcium disodium EDTA if the usage of the 
substance was substantially extended. 
4. The Committee continued to be concerned about the usage of additives in foods intended 
for consumption by infants less than 2 years of age. Calcium disodium EDTA is an 
effective séquestrant of mineral elements and should not be used in such foods. 
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26 REPORT OF THE SCIENTIFIC COMMITTEE FOR FOOD ON COLOURING MATTERS AUTHORIZED 
FOR USE IN FOODSTUFFS INTENDED FOR HUMAN CONSUMPTION 
(Opinion expressed 16 September 1977) 
TERMS OF REFERENCE 
The Committee was asked to review the safety in use of certain colouring matters not 
included in its first report on colouring matters authorized for use in foodstuffs intended 
for human consumption (June 1975) and to consider information presented subsequently on 
colouring matters included in the earlier report. 
CONCLUSIONS 
1. Colours for which an ADI could be established and which are therefore toxicologically 
acceptable for use in food within these limits: 
citranaxanthin (in feedingstuff for poultry) ADI 0-0.4 mg/kg bw 
to be included in the ADI of 0-5 mgAg bw 
for/*—carotene 
J) —ap 0—8'—car ote nal 
J? —apo—8'carotenoic acid methyl and ethyl esters 
2. Colours for which an ADI was not established but which could be used in food: 
riboflavin—5'—phosphate 
vegetable carbon 
titanium dioxide 
3. Colours for which an ADI could not be established and which are not toxicologically 
acceptable for use in food: 
antheraxanthin oleoresin 
methyl violet (±) 
red 10 Β 
ultramarine 
violet BNP 
BACKGROUND 
1. Following the issue of the Committee's Report of June 1975 Ί-he Commission made enquiries 
as to whether other information was available which would permit the Committee to modify 
or change its opinion. As a result of these enquiries the Commission decided that the 
Committee should be asked for an opinion on the colours not considered in the 1975 Report, 
and information presented subsequently on colours which were included in that Report. 
2. The Committee was provided with information on the specification, uses and toxicological 
properties of these colours. The Committee wishes to reiterate that its opinion relates, 
as requested by the Commission, to the evaluation of the safety in use of these colours, 
and that the reservations of some of its members on the need to use colours continues to 
exist (see paragraph 7 of the Report of June 1975). 
(A) use as a marker should be reconsidered. 
Reports of the Scientific Committee for Food (First Series) 31 December 1975 (88OI/7290). 
27 3. In giving its opinion the Committee has maintained the approach used in its first Report 
in which its principles for assessment including specification are described (paragraphs 
6-11). 
The colours under discussion fall into three of the groupings used in the earlier report: 
— colours for which an ADI could be established and which are therefore toxicologically 
acceptable for use in food within these limits; 
— colours for which an ADI was not established but which nevertheless could be used in 
food; 
— colours for which an ADI could not be established and which are not toxicologically 
acceptable for use in food. 
4. The detailed considerations of the Committee are listed below: 
Citranaxanthin in feedingstuff s for poultry (5', ó'-^ihydro^'-apo-18'— nor— β—caroten-6— 
one) 
No clear evidence exists for the natural occurrence of this carotenoid colour. The 
available metabolic information points to conversion into vitamin A of the greater part 
of absorbed citranaxanthin, the remainder being deposited in various tissues, including 
the egg yolk of birds. 
The long-term study in rats which has recently been completed (using a protocol 
established some 3 or 4 years ago) revealed no adverse findings at all intake levels 
tested, the highest being 86 mgAg bodyweight citranaxanthin. The available 6 months 
dog study and three generation—reproduction study in rats showed no evidence of adverse 
effects on the parameters studied including reproduction and teratogenicity. 
On the basis of these data the Committee established an ADI of 0-4D.4 mgAg bodyweight 
for man. In addition, in view of the metabolic transformation to vitamin A, this ADI 
should be included in the ADI of 0—5 mgAg bodyweight for all carotenoids with 
provitamin A activity established fοτ/β-carotene,/9—apo—8'—carotenal and the methyl and 
ethylesters of>*"—apo-8*—caroteno!c acid (see Committee Report of 25 June 1975). 
Taking into account the ADI and the small amounts that would be used, the Committee has 
no objection on toxicological grounds to the use of this colour as an additive to 
poultry feed. However, the Committee draws attention to the fact that neither the 
nutritional quality of a chicken, nor that of an egg, can be judged on the basis of 
its colour. 
The Committee was aware that carotenoids with provitamin A activity introduced into 
foods may contribute to the total intake from all sources and recommends that these 
nutritional implications be considered in greater depth at a future date. 
The Committee has not been asked to consider the implications of the practice of 
colouring egg yolks by adding citranaxanthin to poultry feed except in terms of safety 
to the consumer. It is aware that other aspects of this question are being discussed 
by the Commission Services in conjunction with the Member States Governments, and by 
the Scientific Committee for Animal Nutrition. 
The Opinion of the Committee has already been transmitted to the Scientific Committee 
for Animal Nutrition. 
Riboflavin-5—phosphate and Riboflavin 
The Committee was presented with information on riboflavin—5'—phosphate and additional 
data to that considered earlier in relation to riboflavin. Since riboflavin—5'— 
phosphate is the normal metabolite of riboflavin, the Committee has no objection to 
the use of this substance to colour food despite the absence of extensive animal 
toxicological data. However, the Committee is of the opinion that, because of the 
photo—chemical instability of this substance, the problem of breakdown products requires 
investigation and that the use of this substance to colour food should not alter 
significantly the average daily intake of riboflavin. The Committee also recommends 
that riboflavin should be maintained in the list of permitted colouring matters, and not 
excluded from the scope of the Directive as was proposed in the Committee's first report 
on colouring matters. 
28 Antheraxanthin Oleoresin 
Antheraxanthin (5,6—epoxy—5,6-<lihydro-ytf,,/ö—carotene—3,3'-diol) , is a xanthophyll which 
occurs naturally in flowers, including the Aztec Marigold. The product intended for 
use as a food colour is a hexane extract of the flower petals. The product contains 
antheraxanthin at a level of about 30$ in the form of a dipalmitate. 
No toxicological information was supplied either on the xanthophylls or on the 
commercial oleoresin intended to be used as a food colour. The Committee recommends 
therefore, that antheraxanthin oleoresin should not be used to colour food. 
Methyl violet 
Methyl violet is a mixture of the hydrochlorides of the more highly methylated 
pararosanilines containing principally tetra-, penta, and hexamethyl derivatives. On 
the basis of the very scanty acute toxicity data available which did not include any 
results of tests by the oral route the Committee could not evalute this colour. 
The Committee understands that the only current use of methyl violet is as a marker 
(e.g. for meat, citrus fruit). The Committee recommends that this substance should not 
be used to colour food and that its use as a marker should be reconsidered. 
Red 10 Β (C.I 17200) 
The structure of this azodye is closely related to that of Red 2 G, which hydrolyses 
slowly in acid solution to give Red 10 B. From the analytical point of view therefore 
all food containing Red 2 G could contain traces of Red 10 B. Significant quantitites 
of this hydrolysis product are likely to be found in products of high acidity and 
subjected to high temperature during processing. This phenomenon is not unique to 
these two colours. Red 10 Β has also been put forward as a colour in its own right. 
Only scanty metabolic information is available on Red 10 B. Information on short- and 
long—term tests in rats and dogs as well as skin painting studies was supplied only as a 
summary prepared by the U.S. Food and Drug Administration. 
These studies showed that Red 10 Β belonged to the class of compounds causing haemolytic 
anaemia and Heinz body formation. The results of the long—term studies were not a 
available in full and could not be examined by the Committee, but even from the summaries 
available they appeared inadequate in terms of numbers of animals used and design, when 
judged by modern standards. No reproduction studies were available but the summary of 
the teratology studies appeared to show no adverse effects. 
On the basis of the data available to it, the Committee was unable to recommend that 
Red 10 Β be used to colour food. In addition Red 2 G should not be used under conditions 
in which significant hydrolysis to Red 10 Β occurs. 
Ultramarine (C.I Pigment Blue 29, CI Pigment Green 24. etc.) 
Ultramarine is a polysulphide of sodium (or potassium lithium, or silver) alumino 
silicate of unknown constitution which is obtained by grinding mineral lapis lazuli or 
by fusing together kaolin, sodium carbonate (or sulphate), sulphur and carbon. 
No information was available on the metabolism of this colour. The short—term study in 
rats established a no—effect level but no other animal data were available. The 
Committee was unable to recommend that ultramarine be used to colour food. 
Violet BNP 
The available data on this colour show that there is no adequate specification and that 
although some long—term studies appear to have been carried out in mice and rats most 
of the results were not available for evaluation and their adequacy could not be estimatedi 
The Committee recommends that Violet BNP should not be used to colour food. 
29 Titanium dioxida 
At the time of its earlier assessment of this colouring matter (June 1975), "the 
Committee had been informed that the principal use was to colour sugar confectionary. 
In the light of the new information presented to it on other potential uses and on 
specification the Committee felt able to recommend its inclusion in the Directive for 
food use in general. 
Vegetable carbon 
The Committee's earlier advice (June 1975), related to "carbon black" as well as to the 
vegetable carbon currently permitted by the Directive under E153 (vegetable carbon 
having the same properties as medicinal carbon). The Committee hae been now informed 
that the only product which complied with its earlier recommendations on limits for 
polycyclic aromatic hydrocarbons was in fact E153. The Committee has also been informed 
that there was an application of this colouring matter in giving the necessary tint to 
the colour of several foodstuffs. The quantities used are not large. In view of its 
use as a traditional therapeutic agent the Committee was therefore able to recommend 
the maintenance of the substance in the Directive for food use in general, despite the 
absence of extensive animal toxicological data. 
30 REPORT OF THE SCIENTIFIC COMMITTEE FOR FOOD ON FORMALDEHYDE IN "GRANA PADANO" CHEESE 
(Opinion expressed 20 October 1977) 
TERMS OF REFERENCE 
To give an opinion on the acceptability on a Community basis from the point of view of the 
health of the consumer, of the use of formaldehyde in the production of "Grana Padano" 
cheese. 
CONCLUSIONS 
The Committee accepts that the provision in the Directive on Preservatives that permits, 
on a national basis, the use of formaldehyde in "Grana Padano" cheese provided that no 
residue is detectable when the cheese is marketed, may be extended to the whole Community. 
BACKGROUND 
The Council Directive making a ninth amendment to the approximation of the laws of the 
Member States concerning the preservatives authorised for use in foodstuffs intended for 
human consumption (74/62/EEC of 17 December 1973)(l) permits Member States to maintain the 
provisions of their national laws relating to the use of formaldehyde in "Grana Padano" 
cheese provided that, when the product is marketed, no residue of formaldehyde is 
detectable in the finished product (2). This provision lapses after 31 December 1977 if 
no further action is taken and the Commission requested the Committee's advice on whether 
from the point of view of the health of the consumer the Directive could be modified to 
allow continuation of this practice on a Community basis, 
TECHNOLOGICAL DATA 
"Grana Padano" cheese is produced in certain defined regions of Italy. It is a hard 
cheese, normally used for grating but sometimes eaten directly. Owing to local circumstances 
the method by which cheese of an acceptable quality is made involved the addition of small 
quantities of formaldehyde to the milk from which the cheese is produced. The 
formaldehyde suppresses the growth of undesirable microbes which, if left to proliferate, 
would cause holes ("blowing") in the finished cheese. 
TOXICOLOGICAL INFORMATION AND EVALUATION 
Following consideration of toxicological data on h exam et hyl e net et ramine (KMT) the 
Committee thought that it was applicable to formaldehyde since under acidic conditions or 
in the presence of proteins, HMT gradually decomposes to yield formaldehyde and ammonia (3) 
(4)· There is a considerable amount of toxicological information on HMT and on 
formaldehyde (5X6X7X8)· This includes the results of biochemical, short-term, long—term 
and reproduction studies« The Committee agreed that as the residues of formaldehyde in 
"Grana Padano" cheese were minimal they were not likely to present a hazard to human 
health· No residue of formaldehyde should be detectable in cheese by an appropriate 
method with a limit of detection of 0·5 ppm. 
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